Recent News

• 04.17.2025 - Aldeyra Therapeutics Appoints Chip Clark to Board of Directors
• 04.03.2025 - Aldeyra Conference Call to Discuss Regulatory Update on Reproxalap in Dry Eye Disease
• 04.03.2025 - Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
• 03.10.2025 - 2025 Leerink Partners Global Healthcare Conference
• 03.10.2025 - Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference
• 02.11.2025 - Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
• 02.04.2025 - Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
• 12.05.2024 - Citi 2024 Global Healthcare Conference
• 12.02.2024 - Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
• 11.21.2024 - Jefferies London Healthcare Conference

Recent Filings

• 04.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.03.2025 - EX-99.1 EX-99.1
• 04.03.2025 - 8-K Current report
• 03.28.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.28.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]